Design Therapeutics reports Q1 EPS (20c), consensus (26c)

“At Design, we began 2024 with a clear vision to advance our portfolio of first- or best-in-class therapies to treat major genetic disorders, using novel small molecules that work with a patient’s natural genome,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. Dr. Shah continued, “Our work in FA is differentiated by the fact that we have been able to increase levels of endogenous frataxin and we look forward to beginning patient trials with our new drug product, DT-216P2, next year. We have also made solid progress enrolling patients in our FECD observational study and remain on track to initiate Phase 1 development for DT-168 later this year. DT-168 has the potential to be the first effective treatment addressing the root cause of this degenerative corneal disease. Behind these clinical-stage programs, we have an exciting pipeline in HD and DM1, resulting in four programs with the potential to deliver clinical proof-of-concept, depending on R&D results, over the next several years under our current cash runway. We believe success in any one of these programs has the potential to generate enormous value for patients and shareholders.”